Project Grant H8G48201

This $199,295 National Science Foundation project grant funded the development of a comparative online simulation tool for COVID-19 vaccine allocation strategies. Funded under the Biological Sciences program (CFDA 47.074), the Fred Hutchinson Cancer Research Center will create a mathematical model of SARS-CoV-2 transmission incorporating multiple vaccines, viral variants, and demographic factors. This model will then be used to develop a free, open-source, online comparative tool allowing up...

The National Science Foundation (NSF) awarded a $448,823 Project Grant under its Social, Behavioral, and Economic Sciences program (CFDA 47.075) to the Trustees of Boston University. This two-year grant, running from September 1, 2023 to August 31, 2025, aims to assess the effectiveness of various health communication tactics employed by federal, state, and local agencies to encourage vaccine uptake. The project will build a database of vaccine messaging from public health agencies, evaluate the...

The National Science Foundation (NSF) awarded a $997,689 Cooperative Agreement under its NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Omnicyte LLC, a minority-owned small business in Branford, CT. The funding supports the design and production of a next-generation COVID-19 vaccine that addresses weaknesses of current vaccines, such as reduced booster effectiveness, short-lived efficacy, and side effects. The project aims to develop a vaccine candidate with improved...

This $3,056,673 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to investigate the immunological mechanisms that contribute to improved antibody response rates in people living with HIV (PLWH) when vaccinated with the Heplisav-B hepatitis B vaccine compared to the standard Engerix-B vaccine. The study has three key objectives: Define the innate immune signatures, including...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $207,262 to develop an mRNA vaccine against Bourbon virus, an emerging tick-borne RNA virus that can infect and cause disease in humans. The primary objective is to evaluate the efficacy of the mRNA vaccine in a mouse model and determine its mechanism of action. A secondary objective is to test different viral antigens and combinations to...

This $2,065,719 federal Project Grant award from the National Institute on Minority Health and Health Disparities (CFDA 93.307 - Minority Health and Health Disparities Research) supports a community-based intervention to increase COVID-19 and influenza vaccination rates among African American/Black and Latino (AABL) populations in New York. The primary goal is to identify the most cost-effective combination of intervention components, including nurse-led shared decision making, text message...

This Project Grant award, provided by the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), will fund a comprehensive study on the impact of minor vaccine consent (VC) laws on COVID-19 vaccine uptake and transmission among adolescents. The $1,266,296 award, effective from September 16, 2024 to March 10, 2025, will support the University of Pittsburgh's research team in developing a legal...

This federal Cooperative Agreement award from the Centers for Disease Control and Prevention (CDC) under the Public Health Emergency Response: Cooperative Agreement for Emergency Response (CFDA 93.354) program provides $5,358,220.00 in funding to the Hawaii Department of Health Children With Special Health Needs - NBS Division. The award's goal is to increase vaccination rates in Hawaii, with a focused effort to boost education and vaccine coverage in populations disproportionately affected by...

This is a Cooperative Agreement award from the Centers for Disease Control and Prevention (CDC) under the Investigations and Technical Assistance program (CFDA 93.283). The $1,980,000 award to Jhpiego Corp, a non-profit global health organization, will strengthen immunization program implementation in the Philippines over a 5-year period from Sep 2024 to Sep 2029. The key products and services to be delivered under this cooperative agreement include research, surveillance, epidemiological...

This is a Cooperative Agreement award from the Centers for Disease Control and Prevention (CDC) under the Strengthening Public Health through Surveillance, Epidemiologic Research, Disease Detection and Prevention program (CFDA 93.326). The award, valued at $18,893,037, was made to Beth Israel Deaconess Medical Center, Inc. (Bidmc) for a prospective observational study of respiratory virus epidemiology in the Greater Boston area. The study will span 5 years, from Aug 1, 2024 to Jul 31, 2029....